(Q37818248)

23 August 2017

1 reference

title

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy (English)

1 reference

acute promyelocytic leukemia

23 August 2017

1 reference

1 reference

1

Massimo Breccia

1 reference

23 August 2017

2

Francesco Lo-Coco

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 December 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

225-234

1 reference

Acute promyelocytic leukemia as a paradigm for targeted therapy

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Acute promyelocytic leukemia: where does it stem from?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Molecular pathogenesis of acute promyelocytic leukaemia and APL variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Treatment of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Acute promyelocytic leukemia: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Treatment of relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Treatment of relapsed or refractory acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

DNA bending is a determinant of calicheamicin target recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Solution structure of the calicheamicin gamma 1I-DNA complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

The human high affinity IgG receptor (Fc gamma RI) signals through the immunoreceptor tyrosine-based activation motif (ITAM) of the gamma chain of Fc epsilon RI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Expression of cell-surface antigens in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Mechanisms of multidrug resistance and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

How does P-glycoprotein recognize its substrates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.543895

10.1517/14712598.2011.543895

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference